“The limits of the great Monopoly of drugs,”

Chronic. In a market campaign, the Stock market or in a game of Monopoly, the action boils down to transactions. The money is used to intermediate a large barter, a convergence of complementary interests, power struggles, large and small calculations. In the field of business, one of the rays most active is certainly one of the health.

Two operations unveiled this week illustrate the excitement and shed light on the reasons. This Thursday, April 19, it became known successively as the giant of the consumer goods Procter & Gamble was going to buy the division of non-prescription drugs, the pharmacist’s German Merck KGaA for eur 3.4 billion and the laboratory nippon Takeda sought to offer its competitor, anglo-irish Shire, a specialist in rare diseases, to some 50 billion euros.

Large checks to deliver the most beautiful nuggets

Two operations, a priori, far removed, both in amount and in level range. Between decongestants for the nose that is purchased by a manufacturer of laundry and treatments for hemophilia referred to by the japanese, there is a whole world. These operations, however, are both the result of a strategic shift that major of major pharmaceutical companies worldwide. These délestent of their activities “low-end” to invest in the pharmacy of point, the one that makes the call to biotechnology, and which often target rare diseases.

The latter market is showing strong growth, nearly 11 % per year, twice the overall growth of the market of medicines. In addition, rare diseases are by definition not common, they allow treatment prices are sometimes very high. The other reason of the current craze for the advanced laboratories is that, in the face of the soaring costs of research and to the uncertainty of the results obtained, the pharmaceutical giants prefer to buy from businesses…

Like this post? Please share to your friends:
Leave a Reply